
Olivier C Manintveld

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3450070/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CT-derived fractional flow reserve (FFRct) for functional coronary artery evaluation in the follow-up of patients after heart transplantation. European Radiology, 2022, 32, 1843-1852.	2.3	5
2	Relation of Iron Status to Prognosis After Acute Coronary Syndrome. American Journal of Cardiology, 2022, 168, 22-30.	0.7	6
3	Future steps in cardio-oncology—a national multidisciplinary survey among healthcare professionals in the Netherlands. Journal of Cancer Survivorship, 2022, , 1.	1.5	4
4	Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation. ESC Heart Failure, 2022, 9, 1239-1247.	1.4	6
5	Dynamic personalized risk prediction in chronic heart failure patients: a longitudinal, clinical investigation of 92 biomarkers (Bio-SHiFT study). Scientific Reports, 2022, 12, 2795.	1.6	9
6	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009238.	1.6	40
7	Gender Differences in Patients With Stable Chest Pain. American Journal of Cardiology, 2022, 171, 84-90.	0.7	3
8	Pseudomonas aeruginosa left ventricular assist device (LVAD) driveline infection acquired from the bathroom at home. American Journal of Infection Control, 2022, 50, 1392-1394.	1.1	1
9	Oral Glucose Tolerance Test for the Screening of Glucose Intolerance Long Term Postâ€Heart Transplantation. Transplant International, 2022, 35, 10113.	0.8	0
10	Heart failure subphenotypes based on repeated biomarker measurements are associated with clinical characteristics and adverse events (Bio-SHiFT study). International Journal of Cardiology, 2022, 364, 77-84.	0.8	2
11	Evaluation of patients with a HeartMate 3 left ventricular assist device using echocardiographic particle image velocimetry. Journal of Ultrasound, 2021, 24, 499-503.	0.7	3
12	Impact of sex differences in coâ€morbidities and medication adherence on outcome in 25Â776 heart failure patients. ESC Heart Failure, 2021, 8, 63-73.	1.4	15
13	Burden of Providing Informal Care for Patients with Atrial Fibrillation. Value in Health, 2021, 24, 236-243.	0.1	9
14	Personalized screening intervals for kidney function in patients with chronic heart failure: a modeling study. Journal of Nephrology, 2021, 34, 1421-1427.	0.9	1
15	Herpes Zoster in Solid Organ Transplantation: Incidence and Risk Factors. Frontiers in Immunology, 2021, 12, 645718.	2.2	15
16	Influence of renal insufficiency preâ€heart transplantation on malignancy risk postâ€heart transplantation. ESC Heart Failure, 2021, 8, 2172-2182.	1.4	2
17	Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomarkers in Medicine, 2021, 15, 247-255.	0.6	2
18	Left ventricular remodelling and prognosis after discharge in newâ€onset acute heart failure with reduced ejection fraction. ESC Heart Failure, 2021, 8, 2679-2689.	1.4	5

OLIVIER C MANINTVELD

#	Article	IF	CITATIONS
19	COVID-19-related myocarditis post-heart transplantation. International Journal of Infectious Diseases, 2021, 107, 34-36.	1.5	3
20	Safety and feasibility of hemodynamic pulmonary artery pressure monitoring using the CardioMEMS device in LVAD management. Journal of Cardiac Surgery, 2021, 36, 3271-3280.	0.3	13
21	Heart failure and promotion of physical activity before and after cardiac rehabilitation (HFâ€aPProACH): a study protocol. ESC Heart Failure, 2021, 8, 3621-3627.	1.4	2
22	Remote hemodynamic guidance before and after left ventricular assist device implantation: short-term results from the HEMO-VAD pilot study. Future Cardiology, 2021, 17, 885-898.	0.5	8
23	Clinical implementation of coronary computed tomography angiography for routine detection of cardiac allograft vasculopathy in heart transplant patients. Transplant International, 2021, 34, 1886-1894.	0.8	9
24	Prediction of long-term hospitalisation and all-cause mortality in patients with chronic heart failure on Dutch claims data: a machine learning approach. BMC Medical Informatics and Decision Making, 2021, 21, 303.	1.5	1
25	Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors. JACC: CardioOncology, 2021, 3, 695-706.	1.7	11
26	Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients. European Heart Journal Cardiovascular Imaging, 2020, 21, 1005-1012.	0.5	7
27	Mycobacterium chelonae, an â€~atypical' cause of an LVAD driveline infection. International Journal of Infectious Diseases, 2020, 92, 127-129.	1.5	9
28	Impact of preoperative liver dysfunction on outcomes in patients with left ventricular assist devices. European Journal of Cardio-thoracic Surgery, 2020, 57, 920-928.	0.6	9
29	The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis. Transplantation, 2020, 104, 1508-1518.	0.5	16
30	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <scp>VIPâ€HF</scp> study. European Journal of Heart Failure, 2020, 22, 1923-1929.	2.9	25
31	Survival following a concomitant aortic valve procedure during left ventricular assist device surgery: an <scp>ISHLT</scp> Mechanically Assisted Circulatory Support (<scp>IMACS</scp>) Registry analysis. European Journal of Heart Failure, 2020, 22, 1878-1887.	2.9	18
32	Mechanical Support in Early Cardiogenic Shock: What Is the Role of Intra-aortic Balloon Counterpulsation?. Current Heart Failure Reports, 2020, 17, 247-260.	1.3	19
33	Aortic root thrombus after left ventricular assist device implantation and aortic valve replacement. ESC Heart Failure, 2020, 7, 3208-3212.	1.4	3
34	Extracorporeal cardiopulmonary resuscitation in out-of-hospital cardiac arrest in relation to organ donation. European Heart Journal, 2020, 41, 3587-3587.	1.0	4
35	COVIDâ€19 in solid organ transplant recipients: a singleâ€center experience. Transplant International, 2020, 33, 1099-1105.	0.8	71
36	Transhepatic echocardiography: a novel approach for imaging in left ventricle assist device patients with difficult acoustic windows. European Heart Journal Cardiovascular Imaging, 2020, 21, 491-497.	0.5	9

#	Article	IF	CITATIONS
37	Monitoring pulmonary pressures during longâ€term continuousâ€flow left ventricular assist device and fixed pulmonary hypertension: redefining alleged pathophysiological mechanisms?. ESC Heart Failure, 2020, 7, 702-704.	1.4	3
38	Incidence of endâ€stage renal disease after heart transplantation and effect of its treatment on survival. ESC Heart Failure, 2020, 7, 533-541.	1.4	29
39	Impact of Continuous Flow Left Ventricular Assist Device Therapy on Chronic Kidney Disease: A Longitudinal Multicenter Study. Journal of Cardiac Failure, 2020, 26, 333-341.	0.7	22
40	Biatrial Versus Bicaval Orthotopic Heart Transplantation: A Systematic Review and Meta-Analysis. Annals of Thoracic Surgery, 2020, 110, 684-691.	0.7	15
41	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices. Europace, 2020, 22, 584-587.	0.7	22
42	Transcatheter closure and prognosis of coronary artery fistulae in heart transplant recipients. EuroIntervention, 2020, 16, 600-602.	1.4	1
43	Acute kidney injury following left ventricular assist device implantation: Contemporary insights and future perspectives. Journal of Heart and Lung Transplantation, 2019, 38, 797-805.	0.3	15
44	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. Journal of the American Society of Echocardiography, 2019, 32, 1000-1009.	1.2	7
45	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. Thrombosis and Haemostasis, 2019, 119, 1947-1955.	1.8	14
46	Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure—The Bioâ€ S HiFT Study. Journal of the American Heart Association, 2019, 8, e009555.	1.6	27
47	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMOâ€VAD pilot study. ESC Heart Failure, 2019, 6, 194-201.	1.4	29
48	Prediction of long-term (> 10 year) cardiovascular outcomes in heart transplant recipients: Value of stress technetium-99m tetrofosmin myocardial perfusion imaging. Journal of Nuclear Cardiology, 2019, 26, 845-852.	1.4	11
49	Modification of a Ventricular Assistance Device for a Hemiplegic Left Ventricular Assist Device Patient. ASAIO Journal, 2019, 65, e12-e13.	0.9	0
50	Monitoring pulmonary artery pressure in chronic heart failure patients and evaluating the treatment effect of MitraClip implantation for functional mitral regurgitation. EuroIntervention, 2019, 15, 418-419.	1.4	5
51	Primary intra-aortic balloon support versus inotropes for decompensated heart failure and low output: a randomised trial. EuroIntervention, 2019, 15, 586-593.	1.4	38
52	Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. Intensive Care Medicine, 2018, 44, 588-597.	3.9	52
53	Left ventricular assist device implantation with and without concomitant tricuspid valve surgery: a systematic review and meta-analysis. European Journal of Cardio-thoracic Surgery, 2018, 54, 644-651.	0.6	26
54	Coronary artery disease in heart transplantation: new concepts for an old disease. Transplant International, 2018, 31, 787-827.	0.8	13

OLIVIER C MANINTVELD

#	Article	IF	CITATIONS
55	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHiFT study. American Heart Journal, 2018, 196, 36-48.	1.2	40
56	18F-FDG PET/CT in the Diagnosis and Management of Continuous Flow Left Ventricular Assist Device Infections: A Case Series and Review of the Literature. ASAIO Journal, 2018, 64, e11-e19.	0.9	31
57	Safety and feasibility of contrast echocardiography for the evaluation of patients with HeartMate 3 left ventricular assist devices. European Heart Journal Cardiovascular Imaging, 2018, 19, 690-693.	0.5	11
58	Pre-operative proteinuria in left ventricular assist devices and clinical outcome. Journal of Heart and Lung Transplantation, 2018, 37, 124-130.	0.3	17
59	Long-Term Mechanical Durability of Left Ventricular Assist Devices: An Urgent Call for Periodic Assessment of Technical Integrity. ASAIO Journal, 2018, 64, 521-528.	0.9	2
60	Derivation and Validation of a Novel Right-Sided Heart Failure Model After Implantation of Continuous Flow Left Ventricular Assist Devices. Circulation, 2018, 137, 891-906.	1.6	183
61	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHiFT study. Kidney International, 2018, 93, 952-960.	2.6	26
62	Realâ€Life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. Clinical Pharmacology and Therapeutics, 2018, 104, 346-355.	2.3	2
63	Acute kidney injury and 1-year mortality after left ventricular assist device implantation. Journal of Heart and Lung Transplantation, 2018, 37, 116-123.	0.3	33
64	Moderate Aortic Stenosis and Reduced Left Ventricular Ejection Fraction: Current Evidence and Challenges Ahead. Frontiers in Cardiovascular Medicine, 2018, 5, 111.	1.1	7
65	Liquid Biopsies to Monitor Solid Organ Transplant Function: A Review of New Biomarkers. Therapeutic Drug Monitoring, 2018, 40, 515-525.	1.0	39
66	Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHiFT Study). Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3954-3964.	1.8	27
67	An unusual case of congestive heart failure in the Netherlands. JMM Case Reports, 2018, 5, e005142.	1.3	3
68	Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant. Experimental and Clinical Transplantation, 2018, 16, 326-332.	0.2	5
69	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. International Journal of Cardiology, 2017, 235, 124-132.	0.8	36
70	Renal function at 1Âyear after cardiac transplantation rather than acute kidney injury is highly associated with long-term patient survival and loss of renal function - a retrospective cohort study. Transplant International, 2017, 30, 788-798.	0.8	16
71	First-Line Support by Intra-Aortic Balloon Pump in Non-Ischaemic Cardiogenic Shock in the Era of Modern Ventricular Assist Devices. Cardiology, 2017, 138, 1-8.	0.6	16
72	Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. American Journal of Cardiology, 2017, 120, 2221-2225.	0.7	16

OLIVIER C MANINTVELD

#	Article	IF	CITATIONS
73	CD16+ Monocytes and Skewed Macrophage Polarization toward M2 Type Hallmark Heart Transplant Acute Cellular Rejection. Frontiers in Immunology, 2017, 8, 346.	2.2	30
74	Hemodynamic deterioration precedes onset of ventricular tachyarrhythmia after Heartmate II implantation. Journal of Cardiothoracic Surgery, 2016, 11, 97.	0.4	4
75	Acute Kidney Injury as a Complication of Cardiac Transplantation. Transplantation, 2016, 100, 1740-1749.	0.5	52
76	lschemic Postconditioning After Routine Thrombus Aspiration During Primary Percutaneous Coronary Intervention: Rationale and Design of the <scp>PO</scp> stconditioning <scp>R</scp> otterdam Trial. Catheterization and Cardiovascular Interventions, 2016, 88, 508-514.	0.7	2
77	Ventricular Arrhythmias inÂPatients With a Continuous-Flow Left Ventricular Assist Device. Journal of the American College of Cardiology, 2016, 68, 323-325.	1.2	13
78	Kinking, thrombosis and need for re-operation in a patient with a left ventricular assist device. Intensive Care Medicine, 2016, 42, 2090-2091.	3.9	1
79	Clinical potential of DNA methylation in organ transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 843-850.	0.3	26
80	Repeated Measurements of NT-pro-B-Type Natriuretic Peptide, Troponin T or C-Reactive Protein Do Not Predict Future Allograft Rejection in Heart Transplant Recipients. Transplantation, 2015, 99, 580-585.	0.5	22
81	Limitation of Infarct Size and No-Reflow byÂIntracoronary Adenosine Depends Critically on Dose and Duration. JACC: Cardiovascular Interventions, 2015, 8, 1990-1999.	1.1	37
82	Improved long-term survival in Dutch heart transplant patients despite increasing donor age: the Rotterdam experience. Transplant International, 2015, 28, 962-971.	0.8	36
83	Vagal nerve stimulation started just prior to reperfusion limits infarct size and no-reflow. Basic Research in Cardiology, 2015, 110, 508.	2.5	53
84	Interleukin-17–producing CD4+ cells home to the graft early after human heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 933-940.	0.3	20
85	Predictors of changes in health status between and within patients 12 months post left ventricular assist device implantation. European Journal of Heart Failure, 2014, 16, 566-573.	2.9	25
86	Rotterdam: Main port for organ transplantation research in the Netherlands. Transplant Immunology, 2014, 31, 200-206.	0.6	1
87	Ischemic postconditioning in human DCD kidney transplantation is feasible and appears safe. Transplant International, 2014, 27, 226-234.	0.8	27
88	Weaning from inotropic support and concomitant betaâ€blocker therapy in severely ill heart failure patients: take the time in order to improve prognosis. European Journal of Heart Failure, 2014, 16, 435-443.	2.9	10
89	A Broken Heart. Journal of Cardiac Surgery, 2014, 29, 794-794.	0.3	0
90	Impact of multiple balloon inflations during primary percutaneous coronary intervention on infarct size and long-term clinical outcomes in ST-segment elevation myocardial infarction: real-world postconditioning. Basic Research in Cardiology, 2014, 109, 403.	2.5	26

#	Article	IF	CITATIONS
91	Percutaneous coronary interventions during ST-segment elevation myocardial infarction: current status and future perspectives. EuroIntervention, 2014, 10, T13-T22.	1.4	5
92	Right atrial and ventricular angiosarcoma. European Heart Journal, 2013, 34, 3361-3361.	1.0	0
93	Computed tomography coronary imaging as a gatekeeper for invasive coronary angiography in patients with newly diagnosed heart failure of unknown aetiology. European Journal of Heart Failure, 2013, 15, 1028-1034.	2.9	21
94	Protection Against Renal Ischemia-Reperfusion Injury by Ischemic Postconditioning. Transplantation, 2013, 95, 1299-1305.	0.5	41
95	Response to "Renal Postconditioning…Pause for Thought?â€, Transplantation, 2013, 96, e53-e54.	0.5	3
96	The Emerging Application of Remote Ischemic Conditioning in the Clinical Arena. Cardiology in Review, 2012, 20, 279-287.	0.6	9
97	Remote Ischemic Conditioning in Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. Circulation Journal, 2012, 76, 2392-2404.	0.7	35
98	Involvement of reperfusion injury salvage kinases in preconditioning depends critically on the preconditioning stimulus. Experimental Biology and Medicine, 2011, 236, 874-882.	1.1	4
99	Interaction Between Pre- and Postconditioning in the <i>In Vivo</i> Rat Heart. Experimental Biology and Medicine, 2009, 234, 1345-1354.	1.1	20
100	Ischemic preconditioning modulates mitochondrial respiration, irrespective of the employed signal transduction pathway. Translational Research, 2008, 151, 17-26.	2.2	23
101	Cardiac effects of postconditioning depend critically on the duration of index ischemia. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1551-H1560.	1.5	94
102	The RISK of ROCK. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2563-H2565.	1.5	33
103	Mitochondrial adaptations within chronically ischemic swine myocardium. Journal of Molecular and Cellular Cardiology, 2006, 41, 980-988.	0.9	54
104	Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway. British Journal of Pharmacology, 2005, 145, 703-711.	2.7	23
105	Myocardium tolerant to an adenosine-dependent ischemic preconditioning stimulus can still be protected by stimuli that employ alternative signaling pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1165-H1172.	1.5	35
106	The Tyrosine Phosphatase Inhibitor Bis(Maltolato)Oxovanadium Attenuates Myocardial Reperfusion Injury by Opening ATP-Sensitive Potassium Channels. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1256-1262.	1.3	31
107	Theophylline Use to Prevent Permanent Pacing in the Contemporary Era of Heart Transplantation: The Rotterdam Experience. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4